SRF/myocardin: A novel molecular axis regulating vascular smooth muscle cell stiffening in hypertension

Cardiovascular Research

Volumn 113, Issue 2, 2017, Pages 120-122

  Lacolley, Patrick ^a,b   Li, Zhenlin ^c,d   Challande, Pascal ^c,e   Regnault, Veronique ^a,b  

^a INSERM UMR S 1116 University of Lorraine   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d Groupe Enzymologie Moléculaire et Fonctionnelle   (France)

^e CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CCG 100602; MYOCARDIN; MYOSIN LIGHT CHAIN KINASE; PROTEIN INHIBITOR; SERUM RESPONSE FACTOR; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN;

ACTIN POLYMERIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL STIFFNESS; ARTERY WALL; ATOMIC FORCE MICROSCOPY; CONTROLLED STUDY; DRUG PROTEIN BINDING; ESSENTIAL HYPERTENSION; HUMAN; HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE CELL; YOUNG MODULUS; HYPERTENSION; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

HUMANS; HYPERTENSION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NUCLEAR PROTEINS; TRANS-ACTIVATORS; VASCULAR STIFFNESS;

EID: 85015251620     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw253     Document Type: Review

References (10)

1. Sehgel NL, Sun Z, Hong Z, Hunter WC, Hill MA, Vatner DE, Vatner SF, Meininger GA. Augmented vascular smooth muscle cell stiffness and adhesion when hypertension is superimposed on aging. Hypertension. 2015;65:370-377.
2. Zhou N, Lee JJ, Stoll S, Ma B, Wiener R, Wang C, Costa KD, Qiu H. Inhibition of SRF/myocardin reduces aortic stiffness by targeting vascular smooth muscle cell stiffening in hypertension. Cardiovasc Res. 2017;113:171-182.
3. Intengan HD, Thibault G, Li JS, Schiffrin EL. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angioten-sin receptor antagonism and converting enzyme inhibition. Circulation. 1999;100:2267-2275.
4. Laurent S, Boutouyrie P. The structural factor of hypertension: large and small artery alterations. Circ Res. 2015;116:1007-1021.
5. Galmiche G, Labat C, Mericskay M, Aissa KA, Blanc J, Retailleau K, Bourhim M, Coletti D, Loufrani L, Gao-Li J, Feil R, Challande P, Henrion D, Decaux JF, Regnault V, Lacolley P, Li Z. Inactivation of serum response factor contributes to decrease vascular muscular tone and arterial stiffness in mice. Circ Res. 2013;112:1035-1045.
6. Johnson LA, Rodansky ES, Haak AJ, Larsen SD, Neubig RR, Higgins PD. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-beta-induced fibrogenesis in human colonic myofibroblasts. Inflamm Bowel Dis. 2014;20:154-165.
7. Minami T, Kuwahara K, Nakagawa Y, Takaoka M, Kinoshita H, Nakao K, Kuwabara Y, Yamada Y, Yamada C, Shibata J, Usami S, Yasuno S, Nishikimi T, Ueshima K, Sata M, Nakano H, Seno T, Kawahito Y, Sobue K, Kimura A, Nagai R, Nakao K. Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice. EMBO J. 2012;31:4428-4440.
8. Han YJ, Hu WY, Chernaya O, Antic N, Gu L, Gupta M, Piano M, de Lanerolle P. Increased myosin light chain kinase expression in hypertension: Regulation by serum response factor via an insertion mutation in the promoter. Mol Biol Cell. 2006;17:4039-4050.
9. Huveneers S, Daemen MJ, Hordijk PL. Between Rho(k) and a hard place: the relation between vessel wall stiffness, endothelial contractility, and cardiovascular disease. Circ Res. 2015;116:895-908.
10. Humphrey JD, Harrison DG, Figueroa CA, Lacolley P, Laurent S. Central artery stiffness in hypertension and aging: a problem with cause and consequence. Circ Res. 2016;118:379-381.